1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31658
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGhosh, Nilasha-
dc.contributor.authorCouette, Nina-
dc.contributor.authorvan Binsbergen, Wouter H-
dc.contributor.authorWeinmann, Sophia C-
dc.contributor.authorJivanelli, Bridget-
dc.contributor.authorShea, Beverley-
dc.contributor.authorBass, Anne R-
dc.contributor.authorBenesova, Karolina-
dc.contributor.authorBingham, Clifton O-
dc.contributor.authorCalabrese, Cassandra-
dc.contributor.authorCappelli, Laura C-
dc.contributor.authorChan, Karmela Kim-
dc.contributor.authorChoy, Ernest-
dc.contributor.authorDaoussis, Dimitrios-
dc.contributor.authorGoodman, Susan-
dc.contributor.authorHudson, Marie-
dc.contributor.authorJamal, Shahin-
dc.contributor.authorLeipe, Jan-
dc.contributor.authorLopez-Olivo, Maria A-
dc.contributor.authorSuarez-Almazor, Maria-
dc.contributor.authorvan der Laken, Conny J-
dc.contributor.authorMeara, Alexa Simon-
dc.contributor.authorLiew, David F L-
dc.contributor.authorKostine, Marie-
dc.date2022-10-
dc.date.accessioned2023-01-12T01:59:54Z-
dc.date.available2023-01-12T01:59:54Z-
dc.date.issued2023-
dc.identifier.citationSeminars in Arthritis and Rheumatism 2023en_US
dc.identifier.issn1532-866X-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/31658-
dc.description.abstractImmune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR). There are no validated classification criteria or outcome measures for these conditions, and adaptation of treatment recommendations from corresponding rheumatic diseases may not be appropriate. We summarized clinical descriptors of ICI-induced IA and ICI-induced PMR and aggregated domains used for these conditions in order to inform the development of a core set of outcome domains.en_US
dc.language.isoeng-
dc.subjectICI-induced inflammatory arthritisen_US
dc.subjectICI-induced polymyalgia rheumaticaen_US
dc.subjectImmune checkpoint inhibitoren_US
dc.subjectOutcome measuresen_US
dc.titleIdentification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleSeminars in Arthritis and Rheumatismen_US
dc.identifier.affiliationDepartment of Medicine, Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, 535 E 70th St, New York, NY, USA.en_US
dc.identifier.affiliationDepartment of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, USA.en_US
dc.identifier.affiliationAmsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL Amsterdam, the Netherlands.en_US
dc.identifier.affiliationDepartment of Rheumatology & Immunology, Duke University, Durham, NC, USA.en_US
dc.identifier.affiliationHospital for Special Surgery, Kim Barrett Memorial Library, HSS Education Institute, New York, NY, USA.en_US
dc.identifier.affiliationSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.en_US
dc.identifier.affiliationDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.en_US
dc.identifier.affiliationDivision of Rheumatology, Johns Hopkins University, Baltimore MD, USA.en_US
dc.identifier.affiliationDepartment of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA.en_US
dc.identifier.affiliationRheumatologyen_US
dc.identifier.affiliationCREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom.en_US
dc.identifier.affiliationDepartment of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece.en_US
dc.identifier.affiliationJewish General Hospital, Lady Davis Institute for medical research and McGill University, Montreal, Quebec, Canada.en_US
dc.identifier.affiliationVancouver Coastal Health, University of British Columbia, Vancouver, BC, Canada.en_US
dc.identifier.affiliationDivision of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Germany.en_US
dc.identifier.affiliationThe University of Texas, MD Anderson Cancer Center, Houston, TX, USA.en_US
dc.identifier.affiliationDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA.en_US
dc.identifier.affiliationClinical Pharmacology and Therapeuticsen_US
dc.identifier.affiliationBordeaux University Hospital, Department of Rheumatology, France.en_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.doi10.1016/j.semarthrit.2022.152110en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36372016-
dc.description.volume58-
dc.description.startpage152110-
local.name.researcherLiew, David F L
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptRheumatology-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Nov 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.